<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1854">
  <stage>Registered</stage>
  <submitdate>28/02/2008</submitdate>
  <approvaldate>28/02/2008</approvaldate>
  <nctid>NCT00626990</nctid>
  <trial_identification>
    <studytitle>Phase III Trial of Anaplastic Glioma Without 1p/19q LOH</studytitle>
    <scientifictitle>Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.</scientifictitle>
    <utrn />
    <trialacronym>CATNON</trialacronym>
    <secondaryid>NCIC CTG CEC.1</secondaryid>
    <secondaryid>EORTC-26053-22054</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Brain and Central Nervous System Tumors</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - temozolomide
Other interventions - DNA methylation analysis
Other interventions - laboratory biomarker analysis
Treatment: surgery - adjuvant therapy
Treatment: surgery - quality-of-life assessment
Treatment: other - radiation therapy

Active Comparator: RT alone - radiation therapy alone

Active Comparator: RT &amp; Concurrent CT - Radiotherapy and concurrent temozolomide chemotherapy

Active Comparator: RT + Adjuvant CT - Radiotherapy plus adjuvant temozolomide chemotherapy

Active Comparator: RT &amp; Concurrent CT + adjuvant CT - Radiotherapy and concurrent chemotherapy plus adjuvant temozolomide chemotherapy


Treatment: drugs: temozolomide
Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.

Other interventions: DNA methylation analysis
MGMT methylation status is used for stratification at randomization.

Other interventions: laboratory biomarker analysis
Prognostic factor analyses

Treatment: surgery: adjuvant therapy
Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.

Treatment: surgery: quality-of-life assessment
Quality of Life analysis will also be used to assess neurological deterioration free progression

Treatment: other: radiation therapy
Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival as measured from the day of randomization</outcome>
      <timepoint>from randomisation till the date of death (assessed up to estimated 15 years from FPI)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>from randomization till the date of disease progression or death (assessed up to estimated 15 years from FPI)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neurological deterioration-free survival</outcome>
      <timepoint>from randomization till the date of neurological deterioration or death (assessed up to estimated 15 years from FPI)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life as assessed by the EORTC Quality of Life Questionnaire (QLQ-C30) version 3 and the Brain Cancer Module-20</outcome>
      <timepoint>from 14 days prior to randomization till five years or death (assessed up to estimated 15 years from FPI)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity as measured by CTEP Active Version of CTCAE</outcome>
      <timepoint>from randomization till disease progression or death (assessed up to estimated 15 years from FPI)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Development of cognitive deterioration as measured by the Mini Mental Status Exam</outcome>
      <timepoint>from start RT till death (assessed up to estimated 15 years from FPI)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Anaplastic oligodendroglioma

               -  Anaplastic oligoastrocytoma

               -  Anaplastic astrocytoma

          -  Newly diagnosed disease

          -  Prior surgery for a low grade tumor is allowed, provided histological confirmation of
             an anaplastic tumor is present at the time of progression

          -  Absence of combined 1p/19q loss

          -  Tumor material available for central 1p/19q assessment, central O6-methylguanine-DNA
             methyltransferase promoter methylation status assessment, isocitrate dehydrogenase
             mutation analysis, and central pathology review

          -  Patients must be on a stable or decreasing dose of steroids for at least two weeks
             prior to randomization

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  ANC = 1.5 x 10^9 cells/L

          -  Platelet count = 100 x 10^9 cells/L

          -  Bilirubin &lt; 1.5 x upper limit of normal (ULN)

          -  Alkaline phosphatase &lt; 2.5 x ULN

          -  AST and ALT &lt; 2.5 x ULN

          -  Serum creatinine &lt; 1.5 x ULN

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No known HIV infection or chronic hepatitis B or hepatitis C infection

          -  No other serious medical condition that would interfere with follow-up

          -  No medical condition that could interfere with oral medication intake (e.g., frequent
             vomiting or partial bowel obstruction)

          -  No other prior malignancies except for any malignancy which was treated with curative
             intent more than 5 years prior to registration and adequately controlled limited basal
             cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ
             of the cervix

          -  No prior or concurrent malignancies at other sites except for surgically cured
             carcinoma in situ of the cervix or nonmelanoma skin cancer

          -  No psychological, familial, sociological, or geographical condition that would
             potentially hamper compliance with the study protocol and follow-up schedule

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior chemotherapy, including carmustine-containing wafers (Gliadel®)

          -  No prior radiotherapy to the brain

          -  No concurrent growth factors unless vital for the patient

          -  No other concurrent investigational treatment

          -  No other concurrent anticancer agents</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>120</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>751</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2024</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>Royal Prince Alfred Hospital - Sydney</hospital>
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>St Vincent'S Hospital - Fitzroy (Melbourne)</hospital>
    <hospital>Austin-Repatriation Medical Centre - Heidelberg</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Alfred Hospital - Prahran</hospital>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2050 - Sydney</postcode>
    <postcode>4102 - Brisbane</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode> - Fitzroy (Melbourne)</postcode>
    <postcode> - Heidelberg</postcode>
    <postcode> - Hobart</postcode>
    <postcode> - Nedlands</postcode>
    <postcode> - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Charleroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Regina, Saskatchewan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Winnipeg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bamberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Regensburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tuebingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Den Haag</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona - (Barcelona)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneve</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bebington, Wirral</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cheltenham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Exeter - Devon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sutton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>European Organisation for Research and Treatment of Cancer - EORTC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>NCIC Clinical Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Radiation Therapy Oncology Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Medical Research Council</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cooperative Trials Group for Neuro-Oncology</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Sharp &amp; Dohme Corp.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
      chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Giving radiation therapy
      together with temozolomide may kill more tumor cells. It is not yet known whether giving
      temozolomide during and/or after radiation therapy is more effective than radiation therapy
      alone in treating anaplastic glioma.

      PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after
      radiation therapy to see how well it works compared to radiation therapy alone in treating
      patients with anaplastic glioma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00626990</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Wolfgang Wick</name>
      <address>Universitatsklinikum Heidelberg</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>